

Northern (NHS) Treatment Advisory Group

Treatment Appraisal: Decision Summary

Date	5 th April 2016
Appraisal & Details	<p>Transanal irrigation (TAI) systems (Peristeen®, Aquaflush®, Irypump® S and QuFora®) for neurogenic bowel dysfunction, chronic constipation and chronic faecal incontinence.</p> <p>The Northern (NHS) Treatment Advisory Group considered an appraisal of transanal irrigation systems for the treatment of chronic constipation, chronic faecal incontinence and neurogenic bowel dysfunction.</p>
Recommendation	<p>The Northern (NHS) Treatment Advisory Group recommends the use of transanal irrigation as an option for treatment when all other treatment options have failed or proved ineffective and if initiated and monitored by a specialist.</p> <p>This is in line with the NICE clinical guideline for the management of faecal incontinence, the Royal College of Surgeons clinical commissioning guide and the European Consensus review.</p> <p>It was agreed that taking into account any patient factors it would seem reasonable to use the system with the lowest acquisition cost first (this is currently the IryPump® S – see cost section below)</p>
Clinical evidence summary	<p>A transanal irrigation system (also known as rectal irrigation) refers to the introduction of water (or other solution) into the rectum and left colon via the anus. The group noted that there is a reasonable volume of evidence for TAI in neurogenic bowel dysfunction however the majority of it is low quality (non-randomised studies, no control groups, small patient numbers etc.) however robust randomised trials are difficult to design and undertake given the invasive nature of TAI adequate blinding is virtually impossible and placebo interventions may be problematic. Efficacy was assessed in a Cochrane review, the review included one small (n=87) 10 week randomised trial which had a small risk of bias. Participants used the Peristeen® system daily or every other day in addition to conservative bowel care or conservative bowel care alone. Statistically significant constipation, neurogenic bowel disease and faecal incontinence sores were found in the TAI group compared to the conservative group. TAI also resulted in a significantly reduced time for bowel care and increased satisfaction.</p> <p>Whilst there have been several cost effectiveness analyses presented at conferences, there are no fully published, independent economic assessments of TAI in the medical literature.</p>
Safety	<p>TAI is generally considered a safe procedure providing users are adequately trained in its use. The most serious risk is that of bowel perforation which can be potentially fatal. The MHRA has issued a medical device alert reminding healthcare professionals to ensure that patients and carers:</p>

Northern (NHS) Treatment Advisory Group

Treatment Appraisal: Decision Summary

	<ul style="list-style-type: none"> Have received comprehensive training and are competent in the use of the system before using it unsupervised Are aware of the risk of bowel perforation, how to recognise the symptoms, and action to be taken. 																																								
Patient Perspective	Chronic constipation and faecal incontinence can be associated with a dramatic decrease in quality of life affecting both physical and mental health. Patients will be pleased that TAI offer a potential option when other options have failed or been ineffective.																																								
Cost analysis summary	<p>Costs will be dependent on the system selected and how often they are used. The table shows the current (<i>Drug Tariff, March 2016</i>) cost of TAI systems available.</p> <table border="1"> <thead> <tr> <th>Product</th> <th>Starter Pack cost</th> <th>Maintenance pack cost (30 days, daily use)</th> <th>Cost for 356 days (daily use, incl. starter pack)</th> </tr> </thead> <tbody> <tr> <td>Aquaflush®</td> <td>£77.73</td> <td>£203.92</td> <td>£2463.59</td> </tr> <tr> <td>Aquaflush® Compact</td> <td>£33.60</td> <td>£120.14</td> <td>£1439.24</td> </tr> <tr> <td>Aquaflush® Quick</td> <td>£78.39</td> <td>£205.66</td> <td>£2484.61</td> </tr> <tr> <td>Irypump® S</td> <td>£489.61</td> <td>N/A</td> <td>£489.61</td> </tr> <tr> <td>Peristeen® (all sizes)</td> <td>£75.49</td> <td>£263.14</td> <td>£3180.54</td> </tr> <tr> <td>Qufora IrriSedo® Mini</td> <td>N/A</td> <td>£118</td> <td>£1400.27</td> </tr> <tr> <td>Qufora IrriSedo® Bed</td> <td>N/A</td> <td>£299.40</td> <td>£3552.88</td> </tr> <tr> <td>QuFora IrriSedo® Cone</td> <td>£77.80</td> <td>£203.32</td> <td>£2456.64</td> </tr> <tr> <td>QuFora® Balloon</td> <td>£70.00</td> <td>£230</td> <td>£2784</td> </tr> </tbody> </table> <p>Additional costs may be incurred for routine maintenance/ replacement of parts, as well as optional accessories such as additional tubing or leg straps. A supply of wipes and disposal bags should also be dispensed alongside equipment. As well as the directly chargeable equipment costs, patient and carer training will incur an additional cost.</p>	Product	Starter Pack cost	Maintenance pack cost (30 days, daily use)	Cost for 356 days (daily use, incl. starter pack)	Aquaflush®	£77.73	£203.92	£2463.59	Aquaflush® Compact	£33.60	£120.14	£1439.24	Aquaflush® Quick	£78.39	£205.66	£2484.61	Irypump® S	£489.61	N/A	£489.61	Peristeen® (all sizes)	£75.49	£263.14	£3180.54	Qufora IrriSedo® Mini	N/A	£118	£1400.27	Qufora IrriSedo® Bed	N/A	£299.40	£3552.88	QuFora IrriSedo® Cone	£77.80	£203.32	£2456.64	QuFora® Balloon	£70.00	£230	£2784
Product	Starter Pack cost	Maintenance pack cost (30 days, daily use)	Cost for 356 days (daily use, incl. starter pack)																																						
Aquaflush®	£77.73	£203.92	£2463.59																																						
Aquaflush® Compact	£33.60	£120.14	£1439.24																																						
Aquaflush® Quick	£78.39	£205.66	£2484.61																																						
Irypump® S	£489.61	N/A	£489.61																																						
Peristeen® (all sizes)	£75.49	£263.14	£3180.54																																						
Qufora IrriSedo® Mini	N/A	£118	£1400.27																																						
Qufora IrriSedo® Bed	N/A	£299.40	£3552.88																																						
QuFora IrriSedo® Cone	£77.80	£203.32	£2456.64																																						
QuFora® Balloon	£70.00	£230	£2784																																						
Financial impact	There is no robust information on how many patients would be eligible for TAI however total numbers are thought to be small. TAI systems are already prescribed by GP's across North East and Cumbria.																																								
PbR: In-tariff	A reduction in bowel dysfunction symptoms may lead to decreased healthcare costs, but there is currently no reliable evidence of this.																																								